from SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA Aubagne, February 17, 2025 Sartorius Stedim Biotech: Information on Document Availability
Sartorius Stedim Biotech Group’s Universal Registration Document 2024 is now available at:
It contains the following information: - Business development for fiscal 2024 and the 2025 forecast for the Sartorius Stedim Biotech Group - Consolidated financial statements for the year ended December 31, 2024
A profile of Sartorius Stedim BiotechSartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros. Currently, more than 9,900 employees are working for customers around the globe.
Phone: +49(0)551.308.1686; petra.kirchhoff@sartorius.com
Visit our Newsroom and follow us on LinkedIn.
Regulatory filing PDF file File: Information on Document Availability |
| Language: | English |
| Company: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | sartorius.presse@sartorius.com |
| Internet: | www.sartorius-stedim.com |
| ISIN: | FR0013154002 |
| Euronext Ticker: | DIM |
| AMF Category: | Annual financial and audit reports / Terms of availability of the annual financial report |
| EQS News ID: | 2087265 |
| End of Announcement | EQS News Service |
2087265 17-Feb-2025 CET/CEST